RxDoctor Payments Data

Halyna Chykyda

Internal Medicine · Port Jefferson, NYNPI 1881073740

Payments from drug & device makers

$3,924in general payments, 2019–2025

Across 39 payments — averaging $100.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$497
  • E.r. Squibb & Sons, L.L.C.$371
  • Biogen$316
  • Johnson & Johnson$239
  • Novo Nordisk$239
  • plus $1K from 10 others

What the payments were for

  • Food & beverage$3,924100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,924 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$178,785
Medicare patients
655
Services billed
1,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide24$33,813
EliquisApixaban33$26,480
FarxigaDapagliflozin Propanediol11$7,979
Ezetimibe29$2,866
Metoprolol Succinate95$1,532
Atorvastatin Calcium143$1,483
Levothyroxine Sodium93$1,134
Rosuvastatin Calcium100$1,108
Albuterol Sulfate HfaAlbuterol Sulfate39$1,044
Pantoprazole Sodium72$994
Fluticasone Propionate60$858
Gabapentin72$797
Potassium Chloride40$779
Mirtazapine19$759
Azelastine Hcl32$659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$26,48033 claims
AstraZenecaFarxiga$1,207$7,97911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Port Jefferson

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →